Racial differences in microRNA and gene expression in hypertensive women

Douglas F Dluzen1, Nicole Noren Hooten1, Yongqing Zhang2

  • 1Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.

Scientific Reports
|October 26, 2016
PubMed

Insights

African American women experience higher rates of hypertension. This study found significant differences in gene and microRNA expression between African American and white hypertensive women, potentially explaining health disparities.

Area of Science:

  • Genomics
  • Cardiovascular Disease Research
  • Health Disparities

Background:

  • Systemic arterial hypertension is a major cause of cardiovascular morbidity and mortality.
  • African Americans, particularly women, face disproportionately higher rates of hypertension incidence, prevalence, and severity.
  • Differential gene expression is implicated in disease susceptibility and may contribute to health disparities.

Purpose of the Study:

  • To investigate gene and microRNA expression differences in African American versus white women with and without hypertension.
  • To identify novel mRNA-microRNA pairs associated with hypertension and race.
  • To explore potential molecular mechanisms underlying hypertension health disparities.

Main Methods:

  • Transcriptional profiling of peripheral blood mononuclear cells from African American and white, normotensive and hypertensive females.
  • Global microRNA expression profiling.
  • Validation of gene expression using RT-qPCR and microRNA target validation in endothelial cells.

Main Results:

  • Thousands of mRNAs were differentially expressed by race and/or hypertension status.
  • Significant gene expression differences were most prominent in African American hypertensive females.
  • Novel differentially-expressed mRNA-microRNA pairs, including MCL1/miR-20a-5p and PLD1/miR-4717-3p, were identified.

Conclusions:

  • Significant gene and microRNA expression differences exist between African American and white hypertensive females.
  • Identified mRNA-microRNA pairs may play a role in hypertension-related pathways and contribute to health disparities.
  • These molecular differences represent potential targets for future hypertension interventions.

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.5K
MicroRNAs01:22

MicroRNAs

12.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
83
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.7K